PreveCeutical Announces Non-Brokered Private Placement

PreveCeutical Medical Inc., a health sciences company based in Vancouver, British Columbia, has announced a non-brokered private placement of up to 20 million units, each priced at $0.03, raising a maximum of $600,000. The company intends to use the proceeds for short loan repayments, audit and accounting fees, patents, and further studies and analysis of rodents and tissues, as well as general working capital purposes.

Each unit consists of one common share and one-half of another share, with each whole warrant entitling the holder to purchase an additional share at an exercise price of $0.06 per share. The warrants will expire two years from the closing of the offering, but their expiry can be accelerated if the closing price of the company's common shares on the Canadian Securities Exchange (CSE) reaches $0.11 or higher for a minimum of ten consecutive trading days. Acceleration of the warrants would require a notice in accordance with the terms of the warrants.

The company also plans to pay finder's fees in connection with the offering. PreveCeutical Medical Inc. is developing innovative options for preventive and curative therapies using organic and nature-identical products. The company's research and development programs include dual gene therapy for diabetes and obesity, the Sol-gel Program, nature-identical peptides for various ailments, nonaddictive analgesic peptides, and a therapeutic product for treating athletes with concussions.

All securities issued under the offering will be subject to a statutory hold period of four months and one day after the closing. The offering remains subject to certain conditions, including confirmation of no objection from the CSE. The securities issued under the offering will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States without registration or an applicable exemption.

The press release, dated September 28, 2026, does not provide a specific date or time for the closing of the offering, nor does it mention any venues or addresses for further details. The company's stock symbols are CSE: PREV, OTCQB: PRVCF, and FSE: 18H0. The release also notes that the offering is subject to the company's ability to secure no objection from the CSE, which is a regulatory body overseeing the Canadian Securities Exchange.

The company's commitment to innovation and research is evident in its diverse portfolio of ongoing projects. PreveCeutical Medical Inc. aims to be a leader in preventive health sciences, with a focus on developing treatments for diabetes and obesity, as well as addressing various other health issues through nature-identical peptides and nonaddictive analgesic solutions. The therapeutic product for treating athletes with concussions is another significant area of focus, highlighting the company's dedication to improving athlete safety and recovery.

The press release concludes by emphasizing the importance of adhering to the United States Securities Act of 1933, as amended, and the statutory hold period for the issued securities. This ensures compliance with regulatory requirements and protects investors from potential legal issues.